In the trial, a TALZENNA plus XTANDI combination regimen offered overall survival (OS) improvement in metastatic ...

Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of ...

According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...

(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the ...

US pharma giant Pfizer today released positive top line results from the final prespecified overall survival (OS) analysis of ...

Kirkland & Ellis has successfully defended the validity of a pharmaceutical company's patent in London's High Court, ...

Investigators examined overall survival among real-world patients with metastatic prostate cancer (mCSPC) initiating enzalutamide vs apalutamide.

Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1268 in its ...

Pharma stock engaged in manufacturing and distributing of pharmaceutical products gained traction on Thursday’s trading ...

Patients with metastatic castration-sensitive prostate cancer are recommended to be treated with enzalutamide tablets.